194 related articles for article (PubMed ID: 26162681)
1. Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.
Hearn JM; Romero-Canelón I; Munro AF; Fu Y; Pizarro AM; Garnett MJ; McDermott U; Carragher NO; Sadler PJ
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3800-5. PubMed ID: 26162681
[TBL] [Abstract][Full Text] [Related]
2. Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.
Hearn JM; Hughes GM; Romero-Canelón I; Munro AF; Rubio-Ruiz B; Liu Z; Carragher NO; Sadler PJ
Metallomics; 2018 Jan; 10(1):93-107. PubMed ID: 29131211
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Organometallic Osmium(II)-p-cymene Complexes.
Păunescu E; Nowak-Sliwinska P; Clavel CM; Scopelliti R; Griffioen AW; Dyson PJ
ChemMedChem; 2015 Sep; 10(9):1539-47. PubMed ID: 26190176
[TBL] [Abstract][Full Text] [Related]
4. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Li Z; Wang Q; Zhang W; Yang Z; Li L
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
[TBL] [Abstract][Full Text] [Related]
5. NMR studies of group 8 metallodrugs:
Needham RJ; Prokes I; Habtemariam A; Romero-Canelón I; Clarkson GJ; Sadler PJ
Dalton Trans; 2021 Sep; 50(37):12970-12981. PubMed ID: 34581369
[TBL] [Abstract][Full Text] [Related]
6. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
7. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
Oommen D; Yiannakis D; Jha AN
Mutat Res; 2016; 784-785():8-15. PubMed ID: 26731315
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells.
van Rijt SH; Mukherjee A; Pizarro AM; Sadler PJ
J Med Chem; 2010 Jan; 53(2):840-9. PubMed ID: 20000847
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells.
Decollogne S; Joshi S; Chung SA; Luk PP; Yeo RX; Nixdorf S; Fedier A; Heinzelmann-Schwarz V; Hogg PJ; Dilda PJ
Gynecol Oncol; 2015 Aug; 138(2):363-71. PubMed ID: 26080289
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Selectivity and Localization of Reactive Oxygen Species (ROS) Induction by Osmium Anticancer Complexes That Circumvent Platinum Resistance.
Coverdale JPC; Bridgewater HE; Song JI; Smith NA; Barry NPE; Bagley I; Sadler PJ; Romero-Canelón I
J Med Chem; 2018 Oct; 61(20):9246-9255. PubMed ID: 30230827
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
13. Exosomes as mediators of platinum resistance in ovarian cancer.
Crow J; Atay S; Banskota S; Artale B; Schmitt S; Godwin AK
Oncotarget; 2017 Feb; 8(7):11917-11936. PubMed ID: 28060758
[TBL] [Abstract][Full Text] [Related]
14. Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells.
van Rijt SH; Romero-Canelón I; Fu Y; Shnyder SD; Sadler PJ
Metallomics; 2014 May; 6(5):1014-22. PubMed ID: 24668459
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.
Fu Y; Habtemariam A; Basri AM; Braddick D; Clarkson GJ; Sadler PJ
Dalton Trans; 2011 Oct; 40(40):10553-62. PubMed ID: 21860862
[TBL] [Abstract][Full Text] [Related]
16. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
17. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
18. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
19. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
20. Euxanthone inhibits glycolysis and triggers mitochondria-mediated apoptosis by targeting hexokinase 2 in epithelial ovarian cancer.
Zou J; Wang Y; Liu M; Huang X; Zheng W; Gao Q; Wang H
Cell Biochem Funct; 2018 Aug; 36(6):303-311. PubMed ID: 29984416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
